emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
Published 5 months ago • 445 plays • Length 2:31Download video MP4
Download video MP3
Similar videos
-
1:15
luspatercept for the treatment of patients with lower-risk mds and esa failure
-
3:47
current and emerging treatment options for lr-mds-associated anemia following esa failure
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
4:28
current and emerging treatment options for mds
-
1:06
update on the commands trial: luspatercept is superior to esa-based therapy in lr-mds
-
3:58
prognosis & advances in treatment strategies for sf3b1-mutant mds
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
7:05
state-of-the-art treatment regimens for lr-mds
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
3:38
a new set of treatment options for low-risk mds
-
4:21
evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
-
2:11
new therapeutic options for low-risk mds
-
1:38
novel treatment options for lr-mds and the importance of clinical trials in this space
-
3:31
promising treatment options emerging for higher-risk mds & the value of clinical trials
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds